不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用免疫系统：管理弥漫性大 B 细胞淋巴瘤的有效方法
英文原题：Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma.
查看英文原题
Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性血液系统疾病，其恶性潜能受肿瘤微环境免疫特征调控。分子通路的快速突破使免疫学方法成为DLBCL治疗的主要支柱，可联合或不联合化疗药物。利妥昔单抗是首个获批用于治疗DLBCL的单克隆抗体。继利妥昔单抗改变治疗格局之后，其他新型免疫制剂，包括嵌合抗原T细胞疗法，重塑了复发/难治性DLBCL的治疗。然而，耐药和难治状态仍是DLBCL治疗中的挑战。为撰写本综述，我们筛选了2010年3月至2022年10月期间Medline、Embase、Cochrane数据库中的文章以及欧洲/北美指南中关于DLBCL的文献。在此，我们讨论将对这种侵袭性淋巴瘤未来治疗产生重大影响的免疫制剂。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous hematological disorder with malignant potential controlled by immunological characteristics of the tumor microenvironment. Rapid breakthrough in the molecular pathways has made immunological approaches the main anchor in the management of DLBCL, with or without chemotherapeutic agents.
Rituximab was the first monoclonal antibody approved for the treatment of DLBCL. Following rituximab that transformed the therapeutic landscape, other novel immunological agents including chimeric antigen T-cell therapy have reshaped the management of relapsed/refractory DLBCL.
However, resistance and refractory state remain a challenge in the management of DLBCL. For this literature review, we screened articles from Medline, Embase, Cochrane databases and the European/North American guidelines from March 2010 through October 2022 for DLBCL.
Here we discuss immunological agents that will significantly affect future treatment of this aggressive type of lymphoma.
论文信息
- 作者
- Visweshwar N、Rico JF、Killeen R、Manoharan A
- 第一作者单位
- Department of Hematology, University of South Florida, Tampa, FL, USA.United States
- 通讯作者单位
- Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.Australia
- 文献类型
- 综述
- 期刊
- Journal of hematology2023 Aug
- 原文标识
- PubMed 37692863 · DOI 10.14740/jh1112
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →